Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Pruritus: Etiology and patient evaluation

Sara B Fazio, MD
Gil Yosipovitch, MD
Section Editors
Robert P Dellavalle, MD, PhD, MSPH
Jeffrey Callen, MD, FACP, FAAD
Deputy Editor
Abena O Ofori, MD


Pruritus (itch) is a common symptom, rather than a specific disease entity, that occurs in a diverse range of skin diseases and may appear as a prominent feature of extracutaneous disorders such as systemic, neurologic, and psychiatric diseases (table 1).

The pathogenesis and etiology of pruritus, as well as the evaluation of the patient with pruritus, will be reviewed here. The treatment of pruritus is discussed separately. (See "Pruritus: Overview of management".)


Pruritus is a common symptom that is experienced by all human beings at some point during the course of life. The frequent occurrence of pruritus is supported by the results of epidemiologic studies. In a large cross-sectional study (n = 11,730), chronic pruritus (pruritus persisting for more than six weeks) was reported in approximately 16 percent of German workers [1]. A separate study of almost 19,000 adults in Norway found that the prevalence of pruritus in the general population was approximately 8 percent [2].


Although the neurologic pathways that lead to itch are not fully understood, it is generally accepted that transmission of signals along unmyelinated, histamine-sensitive, and nonhistamine-sensitive peripheral C-nerve fibers (distinct from the C-nerve fibers that transmit pain) is involved. These fibers represent a minority (up to 5 percent) of C-nerve fibers in the body and are characterized by a slow conduction velocity and extensive terminal branching [3-8]. Histamine-sensitive fibers have an important role in transmission of acute itch and itch in urticaria, while nonhistamine nerve fibers have a significant role in itch transmission of most types of chronic itch, possibly accounting for the poor response of many types of chronic itch to oral antihistamines.

Signal transmission in nerves may be stimulated by the action of a variety of neural mediators on sensory nerve endings in the epidermis, dermal-epidermal junction, and other sites. Mediators that have been identified as potential peripheral or central contributors to pruritus include histamine, proteases, cathepsins, gastrin releasing peptide, opioids, substance P, nerve growth factor, interleukins, and prostaglandins and their respective receptors [9-11]. Of these, the identification of Mas-related G protein-coupled receptors (an itch-specific population of neurons) represents a major advance in understanding chronic itch. These receptors are key for transmission of nonhistaminergic itch [12].


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Dec 2016. | This topic last updated: Fri Sep 23 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Ständer S, Schäfer I, Phan NQ, et al. Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730. Dermatology 2010; 221:229.
  2. Dalgard F, Svensson A, Holm JØ, Sundby J. Self-reported skin morbidity among adults: associations with quality of life and general health in a Norwegian survey. J Investig Dermatol Symp Proc 2004; 9:120.
  3. Schmelz M, Schmidt R, Bickel A, et al. Specific C-receptors for itch in human skin. J Neurosci 1997; 17:8003.
  4. Reddy VB, Iuga AO, Shimada SG, et al. Cowhage-evoked itch is mediated by a novel cysteine protease: a ligand of protease-activated receptors. J Neurosci 2008; 28:4331.
  5. Sun YG, Zhao ZQ, Meng XL, et al. Cellular basis of itch sensation. Science 2009; 325:1531.
  6. Davidson S, Giesler GJ. The multiple pathways for itch and their interactions with pain. Trends Neurosci 2010; 33:550.
  7. Namer B, Carr R, Johanek LM, et al. Separate peripheral pathways for pruritus in man. J Neurophysiol 2008; 100:2062.
  8. Davidson S, Zhang X, Yoon CH, et al. The itch-producing agents histamine and cowhage activate separate populations of primate spinothalamic tract neurons. J Neurosci 2007; 27:10007.
  9. Yosipovitch G. The pruritus receptor unit: a target for novel therapies. J Invest Dermatol 2007; 127:1857.
  10. Yosipovitch G. Recent advances in pruritus - what we have learned and where are we headed. F1000 Med Rep 2010; 2.
  11. Metz M, Ständer S. Chronic pruritus--pathogenesis, clinical aspects and treatment. J Eur Acad Dermatol Venereol 2010; 24:1249.
  12. Sanders KM, Nattkemper LA, Yosipovitch G. Advances in understanding itching and scratching: a new era of targeted treatments. F1000Res 2016; 5.
  13. Ikoma A, Steinhoff M, Ständer S, et al. The neurobiology of itch. Nat Rev Neurosci 2006; 7:535.
  14. Ishiuji Y, Coghill RC, Patel TS, et al. Distinct patterns of brain activity evoked by histamine-induced itch reveal an association with itch intensity and disease severity in atopic dermatitis. Br J Dermatol 2009; 161:1072.
  15. Davidson S, Zhang X, Khasabov SG, et al. Relief of itch by scratching: state-dependent inhibition of primate spinothalamic tract neurons. Nat Neurosci 2009; 12:544.
  16. Yosipovitch G, Ishiuji Y, Patel TS, et al. The brain processing of scratching. J Invest Dermatol 2008; 128:1806.
  17. Ishiuji Y, Coghill RC, Patel TS, et al. Repetitive scratching and noxious heat do not inhibit histamine-induced itch in atopic dermatitis. Br J Dermatol 2008; 158:78.
  18. Ständer S, Weisshaar E, Mettang T, et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol 2007; 87:291.
  19. Yosipovitch G, Bernhard JD. Clinical practice. Chronic pruritus. N Engl J Med 2013; 368:1625.
  20. White-Chu EF, Reddy M. Dry skin in the elderly: complexities of a common problem. Clin Dermatol 2011; 29:37.
  21. Millikan LE. Treating pruritus. What's new in safe relief of symptoms? Postgrad Med 1996; 99:173.
  22. Dawn A, Papoiu AD, Chan YH, et al. Itch characteristics in atopic dermatitis: results of a web-based questionnaire. Br J Dermatol 2009; 160:642.
  23. Mollanazar NK, Smith PK, Yosipovitch G. Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out? Clin Rev Allergy Immunol 2016; 51:263.
  24. Yosipovitch G. Epidemiology of itching in skin and systemic disease. In: Itch: Basic mechanisms and therapy, Yosipovitch G, Greaves MW, Fleischer AB Jr, McGlone F (Eds), Marcel Dekker, Inc., New York 2004. p.183.
  25. Grattan CE, Sabroe RA, Greaves MW. Chronic urticaria. J Am Acad Dermatol 2002; 46:645.
  26. Greco PJ, Ende J. Pruritus: a practical approach. J Gen Intern Med 1992; 7:340.
  27. Konuk N, Koca R, Atik L, et al. Psychopathology, depression and dissociative experiences in patients with lichen simplex chronicus. Gen Hosp Psychiatry 2007; 29:232.
  28. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137:280.
  29. Yosipovitch G, Goon A, Wee J, et al. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000; 143:969.
  30. Chosidow O. Clinical practices. Scabies. N Engl J Med 2006; 354:1718.
  31. Bakker CV, Terra JB, Pas HH, Jonkman MF. Bullous pemphigoid as pruritus in the elderly: a common presentation. JAMA Dermatol 2013; 149:950.
  32. Ponticelli C, Bencini PL. Pruritus in dialysis patients: a neglected problem. Nephrol Dial Transplant 1995; 10:2174.
  33. Ståhle-Bäckdahl M. Uremic pruritus. Clinical and experimental studies. Acta Derm Venereol Suppl (Stockh) 1989; 145:1.
  34. Mettang T, Fritz P, Weber J, et al. Uremic pruritus in patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). The role of plasma histamine and skin mast cells. Clin Nephrol 1990; 34:136.
  35. Gilchrest BA, Stern RS, Steinman TI, et al. Clinical features of pruritus among patients undergoing maintenance hemodialysis. Arch Dermatol 1982; 118:154.
  36. Patel TS, Freedman BI, Yosipovitch G. An update on pruritus associated with CKD. Am J Kidney Dis 2007; 50:11.
  37. Wang H, Yosipovitch G. New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma. Int J Dermatol 2010; 49:1.
  38. Etter L, Myers SA. Pruritus in systemic disease: mechanisms and management. Dermatol Clin 2002; 20:459.
  39. Kremer AE, Martens JJ, Kulik W, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 2010; 139:1008.
  40. Yosipovitch G. Chronic pruritus: a paraneoplastic sign. Dermatol Ther 2010; 23:590.
  41. Rowe B, Yosipovitch G. Malignancy-associated pruritus. Eur J Pain 2016; 20:19.
  42. Yosipovitch G. Epidemiology of itching in skin and systemic disease. In: Itch: Basic mechanisms and therapy, Yosipovitch G, Greaves MW, Fleischer Jr AB, McGlone F (Eds), Marcel Dekker, Inc., New York 2004. p.183.
  43. Siegel FP, Tauscher J, Petrides PE. Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients. Am J Hematol 2013; 88:665.
  44. Lober CW. Should the patient with generalized pruritus be evaluated for malignancy? J Am Acad Dermatol 1988; 19:350.
  45. Pujol RM, Gallardo F, Llistosella E, et al. Invisible mycosis fungoides: a diagnostic challenge. J Am Acad Dermatol 2002; 47:S168.
  46. Fett N, Haynes K, Propert KJ, Margolis DJ. Five-year malignancy incidence in patients with chronic pruritus: a population-based cohort study aimed at limiting unnecessary screening practices. J Am Acad Dermatol 2014; 70:651.
  47. Johannesdottir SA, Farkas DK, Vinding GR, et al. Cancer incidence among patients with a hospital diagnosis of pruritus: a nationwide Danish cohort study. Br J Dermatol 2014; 171:839.
  48. Neilly JB, Martin A, Simpson N, MacCuish AC. Pruritus in diabetes mellitus: investigation of prevalence and correlation with diabetes control. Diabetes Care 1986; 9:273.
  49. Scribner M. Diabetes and pruritus of the scalp. JAMA 1977; 237:1559.
  50. Yamaoka H, Sasaki H, Yamasaki H, et al. Truncal pruritus of unknown origin may be a symptom of diabetic polyneuropathy. Diabetes Care 2010; 33:150.
  51. Blanes M, Belinchón I, Portilla J, et al. Pruritus in HIV-infected patients in the era of combination antiretroviral therapy: a study of its prevalence and causes. Int J STD AIDS 2012; 23:255.
  52. Kaushik SB, Cerci FB, Miracle J, et al. Chronic pruritus in HIV-positive patients in the southeastern United States: its prevalence and effect on quality of life. J Am Acad Dermatol 2014; 70:659.
  53. Yosipovitch G, Greaves MW, Schmelz M. Itch. Lancet 2003; 361:690.
  54. Garman ME, Tyring SK. The cutaneous manifestations of HIV infection. Dermatol Clin 2002; 20:193.
  55. Shirani Z, Kucenic MJ, Carroll CL, et al. Pruritus in adult dermatomyositis. Clin Exp Dermatol 2004; 29:273.
  56. Razykov I, Thombs BD, Hudson M, et al. Prevalence and clinical correlates of pruritus in patients with systemic sclerosis. Arthritis Rheum 2009; 61:1765.
  57. El-Baalbaki G, Razykov I, Hudson M, et al. Association of pruritus with quality of life and disability in systemic sclerosis. Arthritis Care Res (Hoboken) 2010; 62:1489.
  58. Haber JS, Valdes-Rodriguez R, Yosipovitch G. Chronic Pruritus and Connective Tissue Disorders: Review, Gaps, and Future Directions. Am J Clin Dermatol 2016; 17:445.
  59. Valdes-Rodriguez R, Rowe B, Lee HG, et al. Chronic Pruritus in Primary Sjögren's Syndrome: Characteristics and Effect on Quality of Life. Acta Derm Venereol 2016.
  60. Szarvas S, Harmon D, Murphy D. Neuraxial opioid-induced pruritus: a review. J Clin Anesth 2003; 15:234.
  61. Joshi SS, Ortiz S, Witherspoon JN, et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 2010; 116:3916.
  62. Manousaridis I, Mavridou S, Goerdt S, et al. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management. J Eur Acad Dermatol Venereol 2013; 27:11.
  63. Hanaizi Z, van Zwieten-Boot B, Calvo G, et al. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 2012; 48:237.
  64. Fischer A, Rosen AC, Ensslin CJ, et al. Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4. Dermatol Ther 2013; 26:135.
  65. Reich A, Ständer S, Szepietowski JC. Drug-induced pruritus: a review. Acta Derm Venereol 2009; 89:236.
  66. Padda MS, Sanchez M, Akhtar AJ, Boyer JL. Drug-induced cholestasis. Hepatology 2011; 53:1377.
  67. Lane JE, McKenzie JT, Spiegel J. Brachioradial pruritus: a case report and review of the literature. Cutis 2008; 81:37.
  68. Bernhard JD, Bordeaux JS. Medical pearl: the ice-pack sign in brachioradial pruritus. J Am Acad Dermatol 2005; 52:1073.
  69. Mirzoyev SA, Davis MD. Brachioradial pruritus: Mayo Clinic experience over the past decade. Br J Dermatol 2013; 169:1007.
  70. Wallengren J, Sundler F. Brachioradial pruritus is associated with a reduction in cutaneous innervation that normalizes during the symptom-free remissions. J Am Acad Dermatol 2005; 52:142.
  71. Goodkin R, Wingard E, Bernhard JD. Brachioradial pruritus: cervical spine disease and neurogenic/neuropathic [corrected] pruritus. J Am Acad Dermatol 2003; 48:521.
  72. Marziniak M, Phan NQ, Raap U, et al. Brachioradial pruritus as a result of cervical spine pathology: the results of a magnetic resonance tomography study. J Am Acad Dermatol 2011; 65:756.
  73. Kavak A, Dosoglu M. Can a spinal cord tumor cause brachioradial pruritus? J Am Acad Dermatol 2002; 46:437.
  74. Fleuret C, Dupré-Goetghebeur D, Person H, et al. [Brachioradial pruritus revealing an ependymoma]. Ann Dermatol Venereol 2009; 136:435.
  75. Savk O, Savk E. Investigation of spinal pathology in notalgia paresthetica. J Am Acad Dermatol 2005; 52:1085.
  76. Oaklander AL, Bowsher D, Galer B, et al. Herpes zoster itch: preliminary epidemiologic data. J Pain 2003; 4:338.
  77. Wood GJ, Akiyama T, Carstens E, et al. An insatiable itch. J Pain 2009; 10:792.
  78. Koeppel MC, Bramont C, Ceccaldi M, et al. Paroxysmal pruritus and multiple sclerosis. Br J Dermatol 1993; 129:597.
  79. Brenaut E, Marcorelles P, Genestet S, et al. Pruritus: an underrecognized symptom of small-fiber neuropathies. J Am Acad Dermatol 2015; 72:328.
  80. Nakamizo S, Miyachi Y, Kabashima K. Treatment of neuropathic itch possibly due to trigeminal trophic syndrome with 0.1% topical tacrolimus and gabapentin. Acta Derm Venereol 2010; 90:654.
  81. Cohen OS, Chapman J, Lee H, et al. Pruritus in familial Creutzfeldt-Jakob disease: a common symptom associated with central nervous system pathology. J Neurol 2011; 258:89.
  82. Shabtai H, Nisipeanu P, Chapman J, Korczyn AD. Pruritus in Creutzfeldt-Jakob disease. Neurology 1996; 46:940.
  83. Kretzmer GE, Gelkopf M, Kretzmer G, Melamed Y. Idiopathic pruritus in psychiatric inpatients: an explorative study. Gen Hosp Psychiatry 2008; 30:344.
  84. Yamamoto Y, Yamazaki S, Hayashino Y, et al. Association between frequency of pruritic symptoms and perceived psychological stress: a Japanese population-based study. Arch Dermatol 2009; 145:1384.
  85. Fruensgaard K. Neurotic excoriations. A controlled psychiatric examination. Acta Psychiatr Scand Suppl 1984; 312:1.
  86. Arnold LM, Auchenbach MB, McElroy SL. Psychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment. CNS Drugs 2001; 15:351.
  87. Mutasim DF, Adams BB. The psychiatric profile of patients with psychogenic excoriation. J Am Acad Dermatol 2009; 61:611.
  88. van Laarhoven AI, Walker AL, Wilder-Smith OH, et al. Role of induced negative and positive emotions in sensitivity to itch and pain in women. Br J Dermatol 2012; 167:262.
  89. Papoiu AD, Wang H, Coghill RC, et al. Contagious itch in humans: a study of visual 'transmission' of itch in atopic dermatitis and healthy subjects. Br J Dermatol 2011; 164:1299.
  90. Schut C, Grossman S, Gieler U, et al. Contagious itch: what we know and what we would like to know. Front Hum Neurosci 2015; 9:57.
  91. Berger TG, Shive M, Harper GM. Pruritus in the older patient: a clinical review. JAMA 2013; 310:2443.
  92. Namer B. Age related changes in human C-fiber function. Neurosci Lett 2010; 470:185.
  93. Valdes-Rodriguez R, Mollanazar NK, González-Muro J, et al. Itch prevalence and characteristics in a Hispanic geriatric population: a comprehensive study using a standardized itch questionnaire. Acta Derm Venereol 2015; 95:417.
  94. Rimoin LP, Kwatra SG, Yosipovitch G. Female-specific pruritus from childhood to postmenopause: clinical features, hormonal factors, and treatment considerations. Dermatol Ther 2013; 26:157.
  95. Ständer S, Stumpf A, Osada N, et al. Gender differences in chronic pruritus: women present different morbidity, more scratch lesions and higher burden. Br J Dermatol 2013; 168:1273.
  96. Van Loey NE, Bremer M, Faber AW, et al. Itching following burns: epidemiology and predictors. Br J Dermatol 2008; 158:95.
  97. Lee SS, Yosipovitch G, Chan YH, Goh CL. Pruritus, pain, and small nerve fiber function in keloids: a controlled study. J Am Acad Dermatol 2004; 51:1002.
  98. Papa CM. Winter itch, dry skin. J Med Soc N J 1980; 77:817.